DermTech Helps Detect Skin Cancer Through a Smart Sticker Instead of a Scalpel | News Direct

DermTech Helps Detect Skin Cancer Through a Smart Sticker Instead of a Scalpel Dr. Julie Karen partners with DermTech and YourUpdate TV on a nationwide media tour to discuss the innovative and painless way to get your moles tested for melanoma.

News release by YourUpdateTV

facebook icon linkedin icon twitter icon pinterest icon email icon New York,NY | May 24, 2021 09:00 AM Eastern Daylight Time

A video accompanying this announcement is available at:

Dr. Julie Karen partners with DermTech and YourUpdate TV on a nationwide media tour to discuss the innovative and painless way to get your moles tested for melanoma.

Would it surprise you to know that one in five Americans develops skin cancer during her or his lifetime?

In fact, every hour of every day one American dies from melanoma. It is the deadliest of skin cancers, and one of the most common cancers diagnosed in the U.S.

Because of the nation-wide closures of dermatology offices during the pandemic, the number of skin cancers diagnosed during March-May 2020 decreased by 43% compared to the same timeframe in 2019. This means there is a potential backlog of undiagnosed skin cancers.

Even prior to the pandemic, only 16 percent of Americans ages 18-29 surveyed in a 2018 study stated that they visited a dermatologist’s office in the past 12 months.

What if there were innovative and painless ways to get your moles checked at home via a telehealth appointment and under clinician supervision?

DermTech has a proprietary innovative technology platform that identifies signs of melanoma at the genomic level and allows dermatologists to detect melanoma earlier and more accurately.

The DermTech Melanoma Test analyzes’s genes in your skin sample that is collected using Smart StickersTM, and with a 99% negative predictive value meaning there is a less than 1% probability of the test missing a melanoma when administered properly.

Simply press the Smart StickerTM on the suspicious spot or mole; the adhesive sticker safely collects your cellular material so it can be transported to DermTech’s onsite Gene Lab where laboratory scientists look at the molecular level for RNA and DNA that are linked to melanoma.

Results are shared with your dermatology provider within 3-5 days.

DermTech’s test can also be performed with a doctor’s order and remote sample collection (at your home) under clinician supervision.

In honor of Melanoma and Skin Cancer Awareness Month taking place this month, DermTech also launched its #Stickit2Melanoma campaign to urge people to get proactive about their skin exams. DermTech is pledging up to $1 million over the next four years to raise awareness about the importance of skin exams and making them accessible. For every #Stickit2Melanoma pledge to have a skin exam with a clinician, DermTech will make a $5 donation to its nonprofit partner organizations focused on skin health. To join #Stickit2Melanoma, schedule a skin exam with your doctor, take the pledge at and encourage your community to do the same.

For more information visit:

About YourUpdateTV:

YourUpdateTV is a social media video portal for organizations to share their content. It includes separate channels for Health and Wellness, Lifestyle, Media and Entertainment, Money and Finance, Social Responsibility, Sports and Technology.

About DermTech:

DermTech is the leading genomics company in dermatology and is creating a new category of medicine, precision dermatology, enabled by our non-invasive skin genomics platform. DermTech’s mission is to transform dermatology with our non-invasive skin genomics platform, to democratize access to high quality dermatology care, and to improve the lives of millions. DermTech provides genomic analysis of skin samples collected non-invasively using an adhesive patch rather than a scalpel. DermTech markets and develops products that facilitate the early detection of skin cancers, and is developing products that assess inflammatory diseases and customize drug treatments. For additional information on DermTech, please visit DermTech’s investor relations site at:

Forward-Looking Statements:

This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. The expectations, estimates, and projections of DermTech may differ from its actual results and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, expectations with respect to: the performance, patient benefits, cost‑effectiveness, commercialization and adoption of DermTech’s products and the market opportunity therefor. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Most of these factors are outside of the control of DermTech and are difficult to predict. Factors that may cause such differences include, but are not limited to: (1) the outcome of any legal proceedings that may be instituted against DermTech; (2) DermTech’s ability to obtain additional funding to develop and market its products; (3) the existence of favorable or unfavorable clinical guidelines for DermTech’s tests; (4) the reimbursement of DermTech’s tests by Medicare and private payors; (5) the ability of patients or healthcare providers to obtain coverage of or sufficient reimbursement for DermTech’s products; (6) DermTech’s ability to grow, manage growth and retain its key employees; (7) changes in applicable laws or regulations; (8) the market adoption and demand for DermTech’s products and services together with the possibility that DermTech may be adversely affected by other economic, business, and/or competitive factors; and (9) other risks and uncertainties included in (x) the “Risk Factors” section of the most recent Annual Report on Form 10-K filed by DermTech with the Securities and Exchange Commission (the “SEC”), and (y) other documents filed or to be filed by DermTech with the SEC. DermTech cautions that the foregoing list of factors is not exclusive. You should not place undue reliance upon any forward-looking statements, which speak only as of the date made. DermTech does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based.

Media Contact:

Sophia Hatef

Crowe PR


Sarah Dion



Contact Details


+1 212-736-2727